ICP-MS in QC: Qualification, Blanks and Interference Control

To distinguish an ICP-MS problem from a preparation or matrix problem, compare evidence from different parts of the measurement chain. A low instrument blank does not clear the preparation process. A satisfactory tune does not prove freedom from spectral interference in the sample. Qualification, method validation and routine controls must therefore answer separate, connected questions.

Define the elements, matrices and concentrations that matter, then choose references, blanks and interference challenges that test those conditions. The tables below provide a planning framework and an illustrative investigation, without customer data or universal numerical limits. The objective is a defensible interpretation of elemental-impurity results, not repeated optimisation until an acceptable number appears.

Intended use and analytical interfaces

ICP-MS measures ions produced using an inductively coupled plasma and separated by mass-to-charge ratio. In solution analysis, preparation, uptake, nebulisation, aerosol transport, plasma, interface, analyser and detector all contribute. This is different from conventional molecular LC-MS. A total-element result after digestion does not identify the original chemical species or prove its toxicological form.

Define the measurand before selecting tests: which element, in which material, reported on which basis and over what interval? Record the matrices, preparation routes, dilutions and required reporting capability. Trace the concentration in the measurement solution back to the original sample using the actual mass, volumes and units. The concentration relevant to an instrument test is not automatically the product specification.

ICH Q3D(R2) is listed by EMA as the current effective version, with EU effect from 24 September 2022. It provides the product-level risk and control context. A permitted daily exposure is not an instrument acceptance limit. Translating the product requirement into an analytical target requires the applicable route, dose, preparation and dilution information; this article does not reproduce PDE tables.

Keep three evidence sets connected: platform qualification, demonstration that the procedure is suitable for its intended purpose, and controls showing that a particular analytical run remained acceptable. A qualified system can still produce a biased result from contaminated preparation or unresolved interference. Equally, one satisfactory spiked sample does not establish qualification of all configured modes.

Installation, configuration and safety

Confirm the installed modules, introduction system, analyser, collision/reaction options where present, detector configuration and software versions against approved requirements. Record utilities and interfaces, including gas supplies, extraction, cooling, electrical provision and waste arrangements. Their required capacities and operating limits must come from the actual configuration and approved site assessment, not a generic checklist copied from another model.

Inspect the documented path from sampling and preparation to the autosampler, tubing, nebuliser and introduction assembly. Materials must be compatible with the acid and matrix and suitable for the elements at the required level. “High purity” on a reagent label is not evidence of an acceptable blank for every element. Include storage, container cleaning and transfer steps in the contamination assessment.

Control access to acquisition methods, mass selection, cell settings, correction equations and processing versions. Define storage, backup/recovery and review responsibilities before routine use. Keep records identifying who accepted the installation and how deviations were resolved. Supplier assistance can provide evidence; the laboratory still decides whether the installed configuration meets its intended use.

Plasma systems involve heat, RF energy, UV radiation, electricity, compressed gases and hazardous chemicals. Keep guards and interlocks intact. Never work on a lit torch or open an energised plasma or high-voltage compartment. Follow the approved shutdown and cooling procedure; servicing beyond authorised operator tasks belongs to qualified personnel. EPA safety material supports the hazard principles, not a pharmaceutical installation specification or a universal cooling time.

Performance evidence: references, tuning and calibration

Build the qualification plan around functions that matter to the intended measurement. Relevant characteristics can include response across the required mass range, mass assignment, resolution, background, short-term stability and performance of the modes actually used. Oxide and doubly charged-ion indicators may inform assessment for suitable configurations. Their materials, definitions and acceptance criteria must be justified; a single ratio cannot prove absence of every sample interference.

Tuning adjusts operating conditions to meet defined objectives. Mass calibration establishes the mass-assignment relationship; verification checks it against appropriate evidence. Concentration calibration relates analytical response to element concentration. Qualification establishes suitability of the installed system for its intended use. Record these activities separately, including changes and the conditions under which the evidence was obtained.

Use suitable reference materials with documented identity, assigned values where relevant, uncertainty/traceability information, expiry or validity, preparation and storage. Assess the stability and compatibility of mixed standards. A verification prepared from the same erroneous stock as the calibration may reproduce the error; appropriate independence increases its diagnostic value. Do not treat a visually clear solution as proof that every element remains stable.

The original study by Lee and colleagues on inorganic reference materials shows why peak selection and possible interferences also deserve attention in blanks and calibration solutions. Its findings inform the reasoning; its experimental conditions do not become QC qualification limits. Preserve configuration-specific spectra, responses and deviations so that later drift can be compared with a meaningful baseline.

Blanks: identify the pathway being challenged

A blank is informative only when its composition, preparation and position in the sequence are known. Define local names in the method rather than relying on “blank” alone. A solution used to establish the calibration origin and a blank taken through digestion answer different questions, even when both begin with the same water and acid.

This is a GuideGxP planning matrix. EPA 6020B separately defines calibration, method and rinse blanks in an environmental method; its numerical criteria and prescribed frequencies are not transferred here. Choose the blank set and acceptance basis from the pharmaceutical procedure, reporting requirement and known contamination risks. Record which controls were actually measured.

Do not automatically subtract a high or variable preparation blank from samples. Determine whether the approved calculation permits correction, whether the blank is representative and stable, and whether uncertainty and reporting capability remain acceptable. Blank correction cannot turn an uncontrolled preparation process into valid measurement. Also investigate spectral interference in the blank itself before calling every positive signal contamination.

Illustrative case, without experimental data: the preparation blank is elevated, while a freshly prepared instrument blank is low. Prioritise the additional preparation pathway: reagent lots, vessels, digestion, transfers, exposure and storage. Compare independent preparations with controlled changes to one suspected factor. A low instrument blank makes persistent common background less likely under those conditions; it does not identify the contaminated item or prove that every sample is unaffected.

Spectral and non-spectral interference require different evidence

Spectral interference adds or overlaps a signal at the monitored m/z. It can arise from other isotopes, polyatomic ions or multiply charged species. Non-spectral effects change uptake, aerosol formation, transport, ionisation or transmission, so the response differs even without a new overlapping peak. Contamination, memory and interference may coexist; the categories guide tests rather than guarantee one exclusive cause.

Choose the approach from the actual interference and instrument capability. A collision gas is not a universal cure, and a reaction mode can introduce other chemistry that requires evaluation. Changing isotope or resolution may affect sensitivity. An elemental analyte with only one suitable isotope cannot be checked by inventing an alternative isotope. Document the limitation and select another supported challenge or measurement strategy.

A correction equation needs evidence that its assumptions and coefficients remain valid for the sample and acquisition mode. Internal standards can track or compensate for demonstrated response effects; they do not automatically remove a spectral overlap on the analyte. Standard addition can help address certain matrix-dependent response effects, but cannot by itself establish freedom from an unresolved additive interference.

In the contrasting branch of the case, preparation blanks remain acceptable, but the apparent result changes with matrix load or differs between suitable isotopes/modes. Investigate interference and matrix response using controlled challenges and, where feasible, an independent procedure. A discrepancy is a clue, not proof of the correct answer. Evaluate standards, preparation and dilution together, and retain every result used to accept or reject a hypothesis.

Method controls, compendial scope and data

Separate the product limit from the performance criteria needed to measure around it. USP ⟨232⟩ addresses elemental-impurity limits; ⟨233⟩ addresses procedures. The USP harmonisation notice specifies 1 May 2026 as the official date of its revised ⟨233⟩ text. Ph. Eur. 2.4.20 is identified in the EDQM harmonisation listing. Obtain the full applicable official chapters before finalising a compendial protocol; the public notices consulted here do not establish every current numerical criterion.

Use Q2(R2) and Q14 principles to connect validation or verification work to intended purpose and method understanding. Assess relevant selectivity, accuracy, precision, range and lower reporting capability with suitable materials. A spike added after preparation investigates different parts of the chain from a spike added before preparation. Neither automatically proves complete recovery of native analyte bound in the original material.

Combine suitable reference materials, independent checks, preparation blanks, relevant interference challenges and ongoing controls according to the approved strategy. Define frequencies, replicate design and acceptance criteria before execution using applicable sources and the procedure’s variability. A satisfactory calibration fit is not sufficient evidence of accuracy, absence of contamination or interference control.

Retain raw signals, selected masses, acquisition and cell settings, calibration model, internal-standard assignments, correction versions, preparation records and calculations. Review sample mass, final volume, dilution factors and reporting units independently. Preserve the distinction between instrument-solution concentration and the reported product result. This article supplies no numerical worked example, so no simulated calculation is presented as laboratory evidence.

Investigation, maintenance and return to service

When a control or result is unexpected, preserve the sequence and classify the pattern before intervening. Ask whether it follows preparation batch, reagent lot, matrix, preceding sample, acquisition mode or elapsed time. Record the hypothesis, comparison and expected discriminating outcome. A documented investigation can include scientifically justified remeasurement; repeated analysis solely to obtain compliance cannot establish validity.

Trend relevant blanks, reference response, internal-standard behaviour and performance indicators under comparable conditions. Separate a matrix-specific shift from progressive loss across references and samples. Choose inspection or cleaning only after assessing the likely pathway, instrument instructions and chemical hazards. Do not intervene on the torch, interface or internal assemblies while energised or hot, and do not bypass protective systems.

Match return-to-service checks to the affected functions: suitable performance checks, calibration verification, blank behaviour and relevant procedure controls. Review possible impact on earlier analyses since the last reliable control and document the basis of that interval. A successful retune or clean reference today does not retrospectively validate a failed preparation batch or unresolved interference.

• Is the reported measurand connected to the actual preparation and calibration?
• Does each blank challenge the pathway claimed?
• Has the selected interference strategy been demonstrated for the relevant matrix?
• Are original data, affected results and the release decision traceable?

Close the investigation with evidence supporting the cause or with an explicit statement of the remaining uncertainty. Record corrective action and the reason the system and procedure are suitable to resume. Keeping an unresolved result under review is more defensible than labelling every abnormal response an instrument problem.

Sources and applicability

Source review: 29 September 2026. Q3D(R2) status and relevant sections, Q2(R2)/Q14, EPA 6020B and the relevant sections of the Lee study were consulted. USP ⟨232⟩ was available as a public introduction; the ⟨233⟩ adoption notice and EDQM 2.4.20 listing were available through indexed public material, not the complete current chapters. EPA 1638 safety section was consulted as an indexed excerpt. Environmental methods and reference-material research are used for scientific principles, not pharmaceutical acceptance limits.

1. EMA. ICH Q3D(R2) Elemental impurities. Current effective version, EU effective 24 September 2022; status checked 29 September 2026.
2. ICH / EMA. Q3D(R2), Step 5. Sections 7–10: concentration limits, speciation, analytical procedures and lifecycle management.
3. USP. ⟨232⟩ Elemental Impurities—Limits (2023). Public introduction only.
4. USP. ⟨233⟩ Elemental Impurities—Procedures. Harmonised-standard adoption notice, 25 April 2025; official date 1 May 2026. Indexed notice; full chapter not accessed.
5. EDQM. Harmonisation status for General Texts: G-07, Ph. Eur. 2.4.20. Public status listing; full chapter not accessed.
6. ICH / FDA. Q2(R2) Validation of Analytical Procedures. Final guidance, March 2024.
7. ICH / FDA. Q14 Analytical Procedure Development. Final guidance, March 2024.
8. US EPA. SW-846 Method 6020B, Revision 2, July 2014. Sections 4, 7.22 and 9: interferences, blanks and quality control. Environmental method; not pharmaceutical acceptance criteria.
9. Lee JW, Min HS, Kim J, Lee KS. A fit-for-purpose nongaseous impurity assay procedure for potential inorganic primary reference materials by inductively coupled plasma mass spectrometry. Accred Qual Assur. 2025;30:117–128. Published online 2 September 2024.
10. US EPA. Method 1638, January 1996, section 5.4: plasma RF/UV hazards. Safety principle only; environmental method.

Related Pharma Lab articles

• Analytical instrument qualification and USP ⟨1058⟩
• Qualification, method validation and system suitability
• LC-MS qualification, contamination and matrix effects